Intraoperative Radiation Therapy in Newly Diagnosed Glioblastoma Multiforme

Official Title

A Multicentre Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)

Summary:

INTRAGO II resembles a multicentric, prospective, randomized, 2-arm, open-label clinical phase III trial which tests if the median progression-free survival (PFS) of patients with newly diagnosed glioblastoma multiforme (GBM) can be improved by the addition of intraoperative radiation therapy (IORT) to standard radiochemotherapy.

Trial Description

Primary Outcome:

  • Median Progression-Free Survival
Secondary Outcome:
  • Median Overall Survival
  • PFS within a 1-2 cm margin around the cavity
  • OS with respect to Age
  • PFS with respect to Age
  • OS with respect to KPS
  • PFS with respect to KPS
  • OS with respect to thickness of anticipated T1-Gd-enhancing (remaining) tumour margin
  • PFS with respect to thickness of anticipated T1-Gd-enhancing (remaining) tumour margin
  • OS with respect to extent of resection
  • PFS with respect to extent of resection
  • OS with respect to MGMT promoter methylation status
  • PFS with respect to MGMT promoter methylation status
  • Quality of Life (QoL) questionnaire
  • Activities of daily living (ADL), assessed using the Barthel Index (Mahoney & Barthel, 1965).
  • Radiation-related (acute / early delayed / late) neurotoxicity

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society